Global Regenerative Medicine Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024
Global Regenerative Medicine Market is expected to reach USD 79.8 billion by 2024, at a Whopping CAGR of 20.5% from 2018 to 2024.
Factors driving the growth of the market are; increasing prevalence of degenerative and chronic diseases, technological advancements in nanotechnology, bioengineering and stem cell therapy, and increasing geriatric population across the globe. Moreover, limited number of organs available through donation and increasing investment by governments and private players is further augmenting the growth of the market. The years used for the assessment are as follows;
Historical year:2014, 2015, and 2016
Forecast period:2018 – 2024
The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;
Obtaining historical data of the market based on news, articles, publications, government websites, annual reports, press releases, white papers, surveys, investor presentation of companies, and other secondary sources
Interacting with key opinion leaders of the market and developing data points based on interaction with them
Study of past trends in the market and their year on year Impact on the market size and share
Analyzing the collected data points
Bridging the data points to calculate the total global regenerative medicine market and its various segments
Anticipating potential risks
Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global regenerative medicine market
Finalizing the overall size and share of the global regenerative medicine market
To analyze market trends, opportunities, drivers, and restraints associated with the global regenerative medicine market
To study market response with respect to the mergers and acquisitions in the industry
To profile key companies operating in the regenerative medicine market and provide their competitive landscape
The research scope for global regenerative medicine market is as follows:
Small Molecules and Biologics
Central Nervous System Diseases
Central & South America
Middle East and Africa
Regenerative medicine has been recognized across the globe as a developing research field that offers the potential to revolutionize patients care. The strong demand of regenerative medicine products has been driven by increasing degenerative and chronic diseases, which place cost pressures on healthcare providers, and technological advancements in nanotechnology, bioengineering and stem cell therapy.
Geographically, the global Regenerative Medicine market is segmented into North America, Europe, Asia-Pacific, Central & South America, and Middle East and Africa. North America held the major share of the global market owing to the technological advancements in tissue engineering, and increasing investments in research and development activities. Moreover, increasing incidence of degenerative diseases and presence of advanced healthcare infrastructure is further propelling the industry growth in the region. The growth of the market in Europe is attributed to increasing aging population, and growing number of chronic diseases. Asia-Pacific is expected to witness the highest CAGR during 2018-2024, owing to increasing prevalence of chronic diseases, and rapidly growing healthcare sector. Moreover, growing development in stem cell therapy and tissue engineering are further propelling the market growth in the region. Furthermore, favorable government policies and increasing awareness among healthcare professionals are also boosting the industry growth in the region.
Some of the key companies operating in the market include Osiris Therapeutics, Inc., Novartis AG, TxCell, Inc., Cellectis, Inc., NuVasive, Inc., Integra LifeSciences Corporation, MiMedx Group, Inc., Cellular Biomedicine Group, Inc., Spark Therapeutics, Inc., and Vericel Corporation among others.